Business Wire

Certa Raises Oversubscribed $35M Series B to Further Reduce Third-Party Management Friction

7.9.2023 16:00:00 EEST | Business Wire | Press release

Share

The all-in-one third-party management platform, Certa, today announced it has raised a 2x oversubscribed Series B led by Fin Capital, and Vertex Ventures Southeast Asia and India, with participation from Tru Arrow Partners. Existing investors Point72 Ventures, BDMI, which is part of Bertelsmann's corporate venture arm Bertelsmann Investments, the family office of Bernard Arnault’s Aglae Ventures, The Chainsmokers-backed Mantis VC, and GOAT Capital also participated in the round. This raise brings the total institutional investment in Certa to $50M to date.

Today’s organizations are increasingly global interconnected ecosystems of thousands of suppliers, partners, and clients. Each relationship adds risks like data security, privacy, and fraud. Additionally, companies deal with ever-increasing compliance burdens, such as the recent Uyghur Forced Labor Prevention Act (UFLPA) in the U.S. and the German Supply Chain Due Diligence Act (LkSG), along with pressing Environmental, Social, and Governance (ESG) goals. A firm's competitive edge depends on its ability to work with third parties efficiently, safely, and swiftly. Existing systems at best offer point solutions which are often a pain to integrate, struggle to manage interconnected risks, and third-party data ends up siloed across multiple systems. Certa provides the most comprehensive and intelligent platform for global third-party management across procurement, compliance, ESG, and legal.

The results achieved by Certa’s clients speak volumes. “Business impact has been tremendous; we’ve been able to reduce our cycle times by over 78 percent,” said Linda Chuan, VP & Chief Procurement Officer at Box.

“We’ve been able to reduce our operating costs by 50 percent year over year and increase our on-time payments from around 40 to 95 percent,” echoed Mark Arrigotti, Head of Finance Operations at Uber.

To date, Certa has helped clients onboard and monitor millions of companies across 120 countries supporting 41 languages.

“This investment in a tough economic environment underscores the demand for a more complete, modern solution to manage third-party relationships,” said Jag Lamba, founder and CEO of Certa. “It is a testament to Certa’s best in class technology and the value we have delivered to clients, many of whom are large Fortune 500 companies. We are energized by the faith put in us by our rockstar investors and believe Certa is poised to be a next-gen category leader in third-party management.”

Certa will use the funding to bolster its go-to-market engine, expand its reach into new high-growth markets like Europe, and accelerate adoption. Since customer feedback is in the company’s DNA, Certa is pioneering the use of advanced Generative AI to streamline third-party ecosystems.

“Managing third parties is more than just risk and compliance - customers are looking for a full stack solution,” said Logan Allin, Managing Partner and Founder of Fin Capital and the newest Certa Board Member. “With its ability to redefine how businesses work and grow together, it’s an honor to partner with Certa on their journey as both an investor and board member.”

For more information, visit www.getcerta.com. Follow Certa on Twitter and Linkedin to stay up to date.

About Certa

Certa helps Fortune 500 firms with global third-party compliance, risk management, and ESG. Certa is a comprehensive platform to manage all third parties globally which can be personalized via a no-code studio and an open architecture with 120+ ready-made integrations.

Certa has been recognized as a Top 50 Procurement Providers to Watch in 2022 by Spend Matters, and a Representative Vendor in Gartner’s 2022 Market Guide for Third Party Risk Management Solutions and IT Vendor Risk Management Solutions.

For more information or to schedule a demo, visit our website, Twitter, and Linkedin.

About Fin Capital

Fin Capital is a global asset manager focused on full life cycle investing in B2B FinTech companies. The firm seeks to add meaningful value beyond capital throughout the partnership lifecycle with its proprietary platform, Lighthouse, hands-on operating playbooks, and deep operational experience. Fin is headquartered in San Francisco with offices in Los Angeles, London, Miami, and New York.

About Vertex Ventures Southeast Asia and India (VVSEAI)

Vertex Ventures Southeast Asia and India partners with founders who are creating innovative, transformative and scalable businesses. It has a long and strong track record of investing in early-stage startups and building champions like Grab, PatSnap, Nium, FirstCry, XPressBees, Licious, 17LIVE, and others. VVSEAI supports its portfolio companies with unmatched operating experience and deep access to the capital, talent, partners and customers they need to build truly global businesses. VVSEAI is one of six major funds in the Vertex Global Network which includes Vertex Ventures Israel, Vertex Ventures China, Vertex Ventures US, Vertex Ventures HC and Vertex Growth. These funds each focus on investments in their region and industry specialization. With the combined regional expertise and global reach, each team can leverage the Vertex Platform to get a broad view of innovation and share learning experiences across the world.

For more information, please visit: https://www.vertexventures.sg/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lizzy Harris for Certa
lizzy@pipitcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye